

16TH ANNUAL CONFERENCE

# BUSINESS OF BIOTECH

*Alliances Advancing Cancer Care*


Friday 3.10.2023 | Moffitt Cancer Center | Tampa, FL



#MoffittBOB  
[www.moffittip.com](http://www.moffittip.com)



# MOFFITT 2022 INNOVATION INDEX



## AGENDA

8:30am – 9:15am

### BREAKFAST AND NETWORKING

○ **ATRIUM**

9:30am – 11:00am

### WELCOME AND KEYNOTE ADDRESS

- **Gary Glick, PhD**  
Founder & CEO – Odyssey Therapeutics  
*interviewed by*  
**Krystyna Kowalczyk**  
CEO, OncoBay Clinical  
○ **COUCH AUDITORIUM**

11:00am – 11:30am

### BREAK

11:30am – 12:15pm

### KEYNOTE ADDRESS

- **Vikas Sinha**  
President & CFO – AlloVir  
Chief Financial Officer – ElevateBio  
*interviewed by*  
**Jordan Saxe**  
Sr. Managing Director, Head of Healthcare Listing &  
Capital Markets - Nasdaq  
○ **COUCH AUDITORIUM**

12:15pm – 1:30pm

### LUNCH, NETWORKING & TOURS

○ **ATRIUM**

1:30pm – 2:30pm

### BREAKOUT SESSION

- *CAR-T Therapy in Solid Tumors: Persisting Challenges & New Opportunities*  
**Moderators**  
**Reni Benjamin, PhD**  
Managing Director, JMP Securities  
**Silvan Tuerkcan, PhD**  
Director, Healthcare Equity Research, JMP Securities  
○ **COUCH AUDITORIUM**

### BREAKOUT SESSION

- *Finding Funding Success in the 'New Normal'*  
**Moderator**  
**Michael Margolis, RPh**  
Sr. Managing Director, Co-Head of Healthcare  
Investment Banking, Oppenheimer & Co  
○ **FERMAN CONFERENCE ROOM**

## KEYNOTE INTERVIEW

**Gary Glick, PhD**  
Founder & CEO  
Odyssey Therapeutics



Dr. Gary Glick co-founded Scorpion Therapeutics. Gary started his career as a faculty member at the University of Michigan in Ann Arbor, where he is currently the Werner E. Bachmann emeritus professor of chemistry. While at Michigan, Gary founded Lycera Corp. to develop new therapies for inflammation and cancer based on small molecules that modulate cellular metabolism. Under his direction, Lycera initiated six discovery programs, partnered three of these programs with Merck & Co. in deals collectively valued at over \$600M, and advanced two programs into clinical testing.

Gary also founded FirstWave Bio and IFM Therapeutics. Under his leadership as CEO of IFM Therapeutics, the company progressed three programs from ideation to clinical development and executed three major transactions: in 2017, the company sold two cancer assets to Bristol-Myers Squibb in a deal valued over \$2.3B and in 2019, he directed the sale of IFM's NLRP3 inhibitor program to Novartis for \$1.6B and led the structuring and negotiation of a collaboration and option agreement with Novartis valued at over \$840M to develop inhibitors of the cGAS/STING pathway to treat serious inflammatory and autoimmune diseases. He currently serves as Executive Chairman of IFM Therapeutics.

Gary obtained a Ph.D. degree in organic chemistry from Columbia University and was an NIH postdoctoral fellow at Harvard University. He is the author of more than 100 papers, the inventor on 33 issued U.S. patents and the recipient of numerous awards recognizing his scientific contributions and accomplishments as a life science executive.

**Krystyna Kowalczyk**  
CEO  
OncoBay Clinical



Krystyna Kowalczyk is President and CEO of OncoBay Clinical, a full-service clinical research organization (CRO) focused on complex oncology indications including both immuno-oncology and cellular therapy. Krystyna has spent over 30 years in the research industry starting in translational research and progressive management roles in both small and large CROs. Prior to OncoBay, Krystyna founded Novella Clinical, subsequently acquired by IQVIA, and founded Optimal Research Oncology, subsequently acquired by PPD.

With a history of successfully building research organizations, she was engaged by Moffitt Cancer Center in 2019 to translate Moffitt's vision of a therapeutically specialized CRO facilitating excellence in research into a business reality. Under her leadership, OncoBay grew from concept to revenues in excess of \$20 million in under 3 years spanning COVID. In January of 2023, Krystyna worked to secure a substantial investment from Neuca Clinical Trials, Inc. to expand the organization to over 400 staff with offices in five countries. OncoBay Clinical now supports preclinical development programs for biotech customers including regulatory strategy and clinical and non-clinical development strategy, global regulatory submissions, and transition into the clinic in addition to supporting all phases of research with an expertise in early phase through phase 2 work. Her leadership efforts continue to build the organization into a specialty CRO leveraging scientific excellence and innovative technology to transform clinical research and accelerate the path of drugs to market.

Her most current focus expands to building site networks to increase access to diverse patient populations and accelerate development programs. Krystyna completed her degree at Davidson College.

## KEYNOTE INTERVIEW

### Vikas Sinha

President & CFO, AlloVir  
CFO, ElevateBio



Vikas Sinha brings more than 25 years of experience in executive finance roles within the biopharmaceutical industry. He served as the Chief Financial Officer of Alexion Pharmaceuticals for more than 11 years, where he oversaw the global expansion of the company across 50 countries and revenue growth to more than \$3 billion. Prior to joining Alexion, Vikas held various positions with Bayer AG across the world, including CFO, Bayer Pharma, North America and CFO, Bayer Yakuhin, Japan. He also serves as Chief Financial Officer of ElevateBio and an Independent Director and Audit Committee Chair at Verona.

Vikas received his MBA from the Asian Institute of Management, Manila, Philippines. He is a qualified Chartered Accountant and associate member of the Institute of Chartered Accountants of India and a Certified Public Accountant in the United States.

### Jordan Saxe

Sr. Managing Director  
Head of Healthcare Listings &  
Capital Markets - Nasdaq



Jordan B. Saxe is Head of Healthcare listings and Capital Markets & Senior Managing Director, at Nasdaq (Nasdaq: NDAQ), the world's largest exchange. In this role, Jordan is responsible for leading business development efforts in listings. He brings over twenty years of experience within the exchange field, to bear on his work in guiding companies and their legal & financial advisors on the process of listing on the U.S.'s largest electronic market. Jordan has worked on over 400 Healthcare IPOs and healthcare transactions during his tenure at Nasdaq.

His focus on working with early-stage companies to maximize the financing and visibility opportunities that can be provided by public capital markets means he also works very closely with venture capital, private equity, and investment firms to educate them on the liquidity options Nasdaq can provide. His background is in investment research and capital markets. Jordan works with companies by providing value-added consultative services. He analyzes and interprets market transaction and performance data and educates companies on the benefits of Nasdaq. Jordan completed his Bachelor of Science in Business Admin from the University of Vermont.



# FINDING FUNDING SUCCESS IN THE 'NEW NORMAL'

1:30 p.m. - 2:30 p.m. - Ferman Family Conference Room

## MODERATOR



**Joel Sendek**  
Head of Healthcare Life Sciences Research  
Oppenheimer Investment Banking

Joel Sendek brings a wealth of experience to Oppenheimer both from his days as a senior biotech analyst as well as a corporate biotech executive. Prior to joining Oppenheimer in August 2022, Joel held CFO positions at four different biotech companies over the past nine years, where he was responsible for various financing transactions including two traditional IPOs, two Series C financings, a SPAC IPO and a follow-on equity transaction totally over \$1B in capital raised. Joel has also worked as a Senior Analyst at Lazard covering biotechnology and subsequently as Head of Healthcare equity research group at Stifel. Joel covered over 100 companies during the course of his sell-side career ranging from profitable large-cap to microcap biotech companies. Joel has been recognized by The Wall Street Journal as an All-Star Analyst with a number one ranking for stock picking. Earlier in his career he worked in business development at Progenics Pharmaceuticals and as an investment banker at Goldman Sachs. He has a biochemistry degree from Rice University.

## PANELISTS



**Doug Calder**  
President, Vycellix  
President, VyGen-Bio

Douglas W. Calder's active roles include serving as: President and Board Member of Vycellix™, Inc.; President and Board Member for VyGen-Bio, Inc.; Member of the Board of Directors for NextGenNK, BioFlorida, and; Member of the Society for Natural Immunity. Headquartered on the University of South Florida campus, Vycellix is engineering immune-privileged, cancer-targeting T cells and NK cells without altering the components that control self-recognition and obviating the need for immune-suppressive drugs in the context of allogeneic cell therapies, redefining "off-the-shelf" treatment strategies. Doug has more than 30-years of life science executive experience, in Florida-based biotechnology companies and research institutes including Viragen, Accentia Biopharmaceuticals, Biovest International and the Vaccine & Gene Therapy Institute of Florida, as well as having formerly served as a registered financial portfolio manager with a focus on life science equities with the NYSE-member firms, Gruntal & Co. and Dean Witter Reynolds.



**Lucas de Breed, PhD**  
Director, Investments  
BrightEdge

Dr. Lucas de Breed is Director, Investments at BrightEdge – the ACS's mission-driven venture capital fund. Lucas has over 15 years of experience in Oncology, as a scientist, strategy consultant, VC and entrepreneur. Previously, as a Manager at Deallus, a global strategy consulting firm for large biopharma clients, he led the Oncology business unit and founded the firm's East Coast office. As an Investment Director at INKEF Capital, a leading European VC firm, Lucas led the allocation of \$120 million in US and European therapeutics startups, served on the respective Boards, and realized several exits. He is also the Founder of August Care, Director at Quantum Leap Healthcare, a member of the Scientific Advisory Board of Promontory Therapeutics and a member of the Advisory Board of FIRST, an early-stage investment fund for cardiovascular and regenerative medicine. Lucas holds a PhD in Molecular Oncology from University College London and an MBA from Stanford University.



**Jim Glasheen, PhD**  
President & Co-Founder  
Clade Therapeutics

Over the past 25 years, Jim led efforts to translate biomedical innovations into broader societal impact as an academic, a strategic consultant, a venture investor, and an executive. Previously, he was co-founder and founding President and CEO of Atalanta Therapeutics, Executive Vice Chancellor at UMASS Medical School, co-lead of Life Science Practice at Technology Partners Venture Capital, and a leader within the Pharmaceutical and Medical Products practice at McKinsey & Company. His training includes a post-doctoral fellowship at University of California, Berkeley, a PhD from Harvard University, a Deutscher Akademischer Austauschdienst Fellowship at Universität des Saarlandes and a BS from Duke University.



**Arthur Kuan**  
CEO  
CG Oncology

Arthur Kuan serves as Chief Executive Officer at CG Oncology. Having lost his father to cancer this is personal for him. Arthur was recognized in 2022 by Business Insider's 30 People Under 40 Transforming Healthcare. In 2020, he was named a Forbes 30 Under 30 featured honoree in healthcare. At Moffitt Cancer Center, Arthur serves on the IP Commercialization Strategy Committee. Arthur is a Founding Member of Ally Bridge Group, a global healthcare-focused investment platform, and played an active role in managing the fund's portfolio companies. Previously, Arthur was a member of Themes Investment Partners, a Private Equity fund where he focused on healthcare and biotech investment opportunities. He began his career at Dinova Capital, a MedTech incubator fund, focusing on cross-border technology transfer and new company formation. Arthur received his M.S. in Biotechnology from the Johns Hopkins University and his B.A. in Biology from the University of Pennsylvania.

# CAR-T THERAPY IN SOLID TUMORS: PERSISTING CHALLENGES & NEW OPPORTUNITIES

1:30 p.m. - 2:30 p.m. - Ted and Marty Couch Auditorium

## MODERATOR



Reni Benjamin, PhD  
Managing Director  
JMP Securities

Dr. Reni Benjamin is a Managing Director and Senior Biotechnology Analyst at JMP Securities. His coverage consists of small/mid-cap biotechnology companies in the oncology sector. Reni has previously been ranked for recommendation performance and earnings accuracy by StarMine, cited in the Wall Street Journal, Business Week, Financial Times, and Smart Money, and has made appearances on Bloomberg television/radio and CNBC. He presently serves on the Board of Directors of the Centre for Commercialization of Regenerative Medicine (CCRM). Reni received his Ph.D. from the University of Alabama at Birmingham and his Bachelor of Science degree in Biology from Allegheny College.

## MODERATOR



Silvan C. Tuerkcan, PhD  
Director, Healthcare Equity Research  
JMP Securities

Dr. Silvan Tuerkcan is a Director and Equity Research Analyst covering the biotechnology and biopharmaceutical industries. Prior to joining JMP Securities, Silvan was an Executive Director and Senior Research Analyst at both UBS and Oppenheimer & Co. with coverage of small- and mid-cap biotechnology companies. He previously worked in equity research at Goldman Sachs, where he concentrated on large-cap pharmaceuticals. Silvan began his career as a postdoctoral fellow both at Institut Pasteur & Ecole Polytechnique in France and later at the Stanford University School of Medicine. Silvan holds a PhD in Biophysics from France's Ecole Polytechnique, an MSc in Engineering Physics from Germany's TU Munich, and a BSc in Physics from Canada's McGill University.

## PANELISTS



Mary-Lee Dequéant, PhD  
Director, Immuno-Oncology  
CRISPR

Dr. Mary-Lee Dequéant is Senior Director of Immuno-Oncology & In Vivo at CRISPR Therapeutics. She is the preclinical research lead of several allogeneic CAR-T programs such as CTX130™, an investigational first-in-class allogeneic anti-CD70 CAR-T cell therapy currently in clinical trials targeting hematological (T & B cell malignancies) and solid cancers (renal cell carcinoma). Her research group also worked on developing CTX131™, an investigational next generation of allogeneic CAR-T cells targeting CD70+ solid tumors. Initiation of Phase 1/2 clinical trials for next generation CAR T product is planned this year following clearance of its IND application by the FDA in February 2023. Mary-Lee holds a Diplôme d'Ingénieur Grandes Ecoles from the Institut National Agronomique Paris-Grignon, received a Ph.D. in Molecular and Developmental Biology from the University of Kansas Medical Center and completed her postdoctoral training in the Genetics Department at Harvard Medical School.



Will Go, MD, PhD  
Chief Medical Officer  
A2 Bio

Previously VP of clinical development at Kite Pharma (acquired by Gilead), Dr. Go led the ZUMA-1 pivotal study and eventual FDA and EMA approvals of YESCARTA®, the first CAR T cell therapy approved in large B-cell Lymphoma. Earlier in his career, Will played an instrumental role in the clinical development of Vectibix® in colorectal cancer, as well as identifying new predictive biomarkers as a medical director in global clinical development at Amgen. Will earned a BSc in Biology from Carleton College and attended the University of California San Diego's (UCSD) Medical Scientist Training Program. He received his Ph.D. in 2004 with a focus on immunology and completed his M.D. in 2006. At UCSD, Will was the recipient of the California Institute for Regenerative Medicine fellowship award and the American Association of Cancer Institutes' fellowship award studying tumor immunology.



Fred Locke, MD  
Immuno-Oncology Chair  
Dept. of Blood & Marrow Transplant  
& Cellular Immunotherapy  
Moffitt Cancer Center

Dr. Frederick L. Locke is a medical oncologist, cellular therapist, and translational investigator dedicated to discovering and implementing ways to use the immune system against lymphoid malignancies. He holds several leadership roles at Moffitt Cancer Center. As Program Leader for Cellular Immunotherapy at Moffitt, Fred assembled the team of faculty and staff focused on Cellular Immunotherapy, from Moffitt's first CAR-T patient in 2015 to the current pace of treating ~300 CAR-T patients per year. Fred serves in many leadership and committee roles including committees of the American Society of Transplantation and Cellular Therapy, the Leukemia and Lymphoma Society, the American Society of Hematology, and the Association of American Cancer Institutes. Fred has extensive experience in the design and conduct of CAR-T trials and correlative analyses. He is a first or senior author on numerous high impact publications, including articles in the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, JAMA Oncology, and Blood.



Amar Patel, MD  
Sr. Director, Hematology/  
Oncology & Cell Therapy Early  
Clinical Development  
Bristol-Myers Squibb

Dr. Patel currently serves as a Senior Director in Early Clinical Development at Bristol Myers Squibb where he focuses on the development of immunologic and cellular therapies for the treatment of cancer. In this role, he collaborates with cross-functional teams to identify novel therapeutic targets and deliver next-generation cellular therapies into the clinic. Amar is also involved in various industry partnerships, business development and corporate strategy activities in the thematic areas of oncology and hematology. Amar holds a BA in Biochemical Sciences from Harvard University and received his MD from the Johns Hopkins School of Medicine. He then completed residency training at UCLA followed by fellowship in Hematology and Oncology at UCSF where he continues to serve as an Assistant Clinical Professor in the Division of Oncology.

# DIAMOND SPONSORS

novocure®



PASCO EDC  
NORTH TAMPA BAY, FLORIDA®

# JOIN THE LIFE SCIENCES CORRIDOR IN PASCO COUNTY, FLORIDA


**FUTURE**  
MOFFITT CANCER CENTER  
SPEROS FL  
775 ACRE DEVELOPMENT

**54%** LOWER COST OF LIVING  
COMPARED TO  
NEW YORK CITY AND  
SILICON VALLEY

**FLORIDA RANKED #1**  
SYSTEM FOR  
HIGHER EDUCATION  
FOR 6TH STRAIGHT YEAR

**21%** OF YOUNG ADULTS  
MIGRATING TO TAMPA  
FROM OUTSIDE  
FLORIDA MOVED  
FROM MAJOR  
NORTHEAST CITIES

**FLORIDA RANKED #1**  
IN NATION FOR ATTRACTING  
AND DEVELOPING A  
SKILLED WORKFORCE!



## READY SITES PROGRAM

- Evaluated industrial ready sites ranging from 100-1,000+ acres
- Contiguous and developable acreage outside the 100 & 500 year flood zones
- Single & multiple users
- Access to industrial quality utilities
- Within 10 miles of an interstate or four-lane highway

- 1 SOFTWIND INDUSTRIAL PARK 103 ACRES
- 2 HAYS ROAD INDUSTRIAL PARK 199 ACRES
- 3 ENTERPRISE SOUTH SUPER PARK 1,066 ACRES
- 4 ZEPHYRHILLS AIRPORT INDUSTRIAL PARK 419 ACRES
- 5 EAGLE INDUSTRIAL PARK 73 ACRES



INTERACT WITH THE SITES  
Explore each Ready Site's  
utilities, transportation  
networks, and aerial property  
views using interactive maps  
and videos.



**PASCO EDC**  
NORTH TAMPA BAY, FLORIDA®



## COMMUNITY PARTNERS

BIOFLORIDA      FLORIDA MEDICAL MANUFACTURERS CONSORTIUM      FLORIDA VENTURE FORUM      GREATER TAMPA CHAMBER OF COMMERCE

PERSONALIZED MEDICAL COALITION      PINELLAS COUNTY EDC      TAMPA BAY INNOVATION CENTER

## GOVERNMENT PARTNER

**Hillsborough County Florida** | **EDI2**  
Economic Development Innovation Initiative

COMING SOON  
17TH ANNUAL CONFERENCE  
**BUSINESS OF BIOTECH**

Look for our email announcing the 2024 date and Keynote Speaker  
To sign up for updates, email: [innovation@moffitt.org](mailto:innovation@moffitt.org)

## OFFICE OF INNOVATION AND INDUSTRY ALLIANCES

Moffitt Cancer Center, a stand-alone institution located in Tampa, Florida, has a major research enterprise dedicated to the prevention and cure of cancer. Moffitt's interdisciplinary research teams and entrepreneurship culture creates a fertile ground for innovation.

For licensing and research collaboration opportunities call 813-745-6828 or email [innovation@moffitt.org](mailto:innovation@moffitt.org)





# THANKS TO OUR SPONSORS

